Astellas pursues legal action over US tacrolimus petition
This article was originally published in Scrip
Astellas is to take legal action against the US FDA after the agency partly denied the company's 2007 citizen's petition requesting bioequivalence studies in transplant patients for generic versions of its immunosuppressant Prograf (tacrolimus).
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.